Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "NFI"

1393 News Found

FDA delays Corcept’s hypertension drug, seeks more evidence
Drug Approval | January 05, 2026

FDA delays Corcept’s hypertension drug, seeks more evidence

The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence


Indian Vice President calls for global recognition of traditional medicine
News | January 05, 2026

Indian Vice President calls for global recognition of traditional medicine

He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world


Indian Pharmacopoeia 2026 debuts with 121 new monographs targeting TB, diabetes, and cancer
News | January 04, 2026

Indian Pharmacopoeia 2026 debuts with 121 new monographs targeting TB, diabetes, and cancer

Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes


Cupid reports record Q3, eyes GCC expansion with Saudi FMCG facility
News | January 03, 2026

Cupid reports record Q3, eyes GCC expansion with Saudi FMCG facility

Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity


China’s top court backs Novo Nordisk, upholds semaglutide patent in landmark IP ruling
News | January 01, 2026

China’s top court backs Novo Nordisk, upholds semaglutide patent in landmark IP ruling

The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments


Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance
Clinical Trials | December 31, 2025

Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance

The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026


Kokilaben Dhirubhai Ambani Hospital makes history with India’s first intercontinental remote robotic surgeries
Hospitals | December 31, 2025

Kokilaben Dhirubhai Ambani Hospital makes history with India’s first intercontinental remote robotic surgeries

The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety


INOVIO’s DNA therapy for rare throat disease gets FDA review
Biotech | December 30, 2025

INOVIO’s DNA therapy for rare throat disease gets FDA review

INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway


One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty
Clinical Trials | December 30, 2025

One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty

The study met its primary endpoint with flying colors


CPHI & PMEC India 2025 ignites pharma innovation and partnerships
News | December 29, 2025

CPHI & PMEC India 2025 ignites pharma innovation and partnerships

For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows